Generalized glucocorticoid resistance or Chrousos syndrome is an extraordinarily rare genetic disorder that can run in families or be sporadic. It is characterized by partial or generalized target-tissue insensitivity to glucocorticoids.
The goal of treatment for generalized glucocorticoid resistance is to reduce excessive ACTH secretion, which in turn reduces the production of more adrenal steroids that have androgenic and mineralocorticoid properties. High dosages of mineralocorticoid-sparing synthetic glucocorticoids, like dexamethasone, are used as a form of treatment to activate the mutant and/or wild-type hGRα and suppress the affected subjects' natural secretion of ACTH. == See also ==